Ad
related to: vancomycin effective against gram negativegoodrx.com has been visited by 100K+ users in the past month
"This free app will find the best local deals." - AOL.com
- Do I Need Insurance?
No! Compare Our Prices to Your
Insurance & Get the Biggest Savings
- Phone Support Available
Our dedicated customer support team
is here to help answer questions.
- Research You Can Rely On
Our team works hard to provide you
with the latest healthcare info.
- GoodRx®: Women’s Health
Save on Common Women’s Health Meds.
Find Resources You Can Count On.
- Do I Need Insurance?
Search results
Results from the WOW.Com Content Network
Vancomycin is a glycopeptide antibiotic medication used to treat certain bacterial infections. [7] It is administered intravenously (injection into a vein) to treat complicated skin infections, bloodstream infections, endocarditis, bone and joint infections, and meningitis caused by methicillin-resistant Staphylococcus aureus. [8]
Infections caused by Gram-negative bacteria, such as Escherichia coli and Klebsiella particularly Pseudomonas aeruginosa. Effective against aerobic bacteria (not obligate/facultative anaerobes) and tularemia. All aminoglycosides are ineffective when taken orally as the stomach will digest the drug before it goes into the bloodstream.
β-Lactam antibiotics are indicated for the prevention and treatment of bacterial infections caused by susceptible organisms. At first, β-lactam antibiotics were mainly active only against gram-positive bacteria, yet the recent development of broad-spectrum β-lactam antibiotics active against various gram-negative organisms has increased their usefulness.
A colored electron microscopy image of methicillin-resistant staphylococcus aureus (), a bacterium commonly targeted by broad-spectrum antibioticsA broad-spectrum antibiotic is an antibiotic that acts on the two major bacterial groups, Gram-positive and Gram-negative, [1] or any antibiotic that acts against a wide range of disease-causing bacteria. [2]
[157] [158] The Infectious Disease Society of America report noted that the number of new antibiotics approved for marketing per year had been declining and identified seven antibiotics against the Gram-negative bacilli currently in phase 2 or phase 3 clinical trials. However, these drugs did not address the entire spectrum of resistance of ...
Narrow-spectrum antibiotics have low propensity to induce bacterial resistance and are less likely to disrupt the microbiome (normal microflora). [3] On the other hand, indiscriminate use of broad-spectrum antibiotics may not only induce the development of bacterial resistance and promote the emergency of multidrug-resistant organisms, but also cause off-target effects due to dysbiosis.
It is particularly effective against gram-positive bacteria — such as Staphylococcus, Streptococcus, and Clostridium species — but can also treat some gram-negative bacterial infections.
Aminoglycoside antibiotics display bactericidal activity against Gram-negative aerobes and some anaerobic bacilli where resistance has not yet arisen but generally not against Gram-positive and anaerobic Gram-negative bacteria. [3] Streptomycin is the first-in-class aminoglycoside antibiotic.